Núria Agustí Garcia
@nagustiga
Followers
267
Following
1K
Media
8
Statuses
121
Hospital Clínic de Barcelona - residency & GynOnc training; PhD researcher- UB; MD Anderson Cancer Center postdoct fellowship; Former @IJGConline fellowship
Joined January 2023
Our latest @JAMANetworkOpen study shows a shift toward surgical de-escalation in gynecologic oncology. Had a great chat with @pedroramirez—how can training programs adapt to keep proficiency in complex procedures?. @dviverosc @headofmelon @RParejaGineOnco @RauhHainMD.
In this episode of the #IJGCconversations, our EIC @pedroramirezMD is joined by Dr. Núria Agustí @nagustiga to discuss: De-escalation in #GynecologicOncology. Don't miss this insightful discussion! .🔗 @pedroramirezMD @HsuMd @JayrajAarthi
0
6
22
Our JAMA Oncology study is now featured in the @IJGConline podcast! Thank you for highlighting our work. Grateful to work with such an amazing team! @dviverosc @headofmelon @NiteckiRoni @RParejaGineOnco @RauhHainMD.
🎙️ New #IJGCConversations Episode!.🚨 Radiation alone vs. Chemoradiation in Intermediate Risk #CervicalCancer with @nagustiga and @dviverosc. 🎧 Tune in now and stay ahead in #GynOnc!.🔗 @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety
0
7
26
RT @HemOncToday: The addition of chemotherapy to radiotherapy was not associated with improved survival among patients with intermediate-ri….
healio.com
The addition of chemotherapy to radiotherapy was not associated with improved survival among patients with intermediate-risk cervical cancer, according to study results published in JAMA Oncology.C...
0
1
0
RT @ENYGO_official: 🚨Exploring ADCs in Platinum-Resistant Ovarian Cancer: Prof Ray-Coquard & Dr Agustí & Dr Strojna . Link: .
0
2
0
RT @IPVSociety: Cervical Cancer treatment studies show no survival advantage of chemoradiotherapy over radiotherapy alone. These results su….
0
12
0
Excited about our JAMA Oncology study! Adding CHT to RT showed no OS benefit in intermediate-risk cervical cancer, aligning with GOG 263 (#SGO2025). Hope this helps refine guidelines & improve patient care. @dviverosc @headofmelon @NiteckiRoni @RParejaGineOnco @RauhHainMD.
Adding chemotherapy to radiotherapy was not associated with improved overall survival for patients with intermediate-risk cervical cancer. @nagustiga
3
8
36
Great presentation on our @JAMANetworkOpen study about surgical trends and future directions in our field! Even better to share this experience in such a beautiful city with wonderful colleagues. #sgo2025 #SGOMtg
2
1
16
RT @OncLive: Last but not least, we were fortunate enough to speak with Núria Agustí Garcia, MD, of @MDAndersonNews, about her study on adj….
0
2
0
RT @IJGConline: 🎙️ Listen to this week's #IJGC podcast as @pedroramirezMD dives into the LANCE Trial breaking down the results of the Feasi….
0
3
0
Emotivo e riuscito congresso. Felice di aver avuto l’opportunità di presentare e di rivedere tutti i colleghi internazionali. Great to exchange insights and reconnect with colleagues! #esgo2025
1
3
17
Our 15-year cohort study explores trends in surgical de-escalation in gynecologic oncology. These findings are transforming patient care but raise important questions about the preparation of fellows in surgical training. @headofmelon @dviverosc @RauhHainMD @NiteckiRoni.
Gynecologic oncology is moving towards less invasive surgical methods and decreased surgery overall, which likely benefits patients but also raises challenges for surgical training and the equitable access.
0
7
38
Excited to share our Green Journal publication! For low-risk #CervicalCancer patients (tumors ≤2 cm), SH showed no compromise in OS in the NCDB. A step forward for less radical approaches. Grateful for the amazing teamwork, particularly with @dviverosc 🤝📚.#GynOnc.
How does survival after simple compared with radical hysterectomy compare for patients with early-stage cervical cancer? Read the study at: @nagustiga, @headofmelon, @RParejaGineOnco, @dviverosc, @NiteckiRoni, @RauhHainMD, @MDAndersonNews
0
1
8
RT @headofmelon: LANCE trial lead-in pilot shows the feasibility of a phase III study to evaluate the efficacy of MIS for interval cytoredu….
0
12
0
Happy to have contributed to this updated SR on SLN in ovarian cancer, a complex technique requiring distinct methodology, developed alongside colleagues with expertise in this area. There is still so much to learn! #OvarianCancer .@victor_lago @NicoloBizzarri @BertaDiazFeijoo.
Key issues in diagnostic accuracy of SLN biopsy in early-stage #ovariancancer: systematic review and meta-analysis. 🔎 @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4
1
0
10
RT @NiteckiRoni: #cancer during #pregnancy is associated with severe maternal and neonatal morbidity. Proud of the entire team for this imp….
0
8
0
Honored to present ‘Survival after simple vs. radical hysterectomy for early-stage cervical cancer’ at the Society of Pelvic Surgeons’ Annual Meeting. A collaborative effort alongside urology and surgical colleagues. Check it out: .@dviverosc
1
0
16
Even among insured patients with ovarian cancer, disparities persist: non-Hispanic Black women are 23% less likely to receive targeted therapies like PARPi or bevacizumab. Time to bridge the gap in equitable cancer care! #HealthEquity #OvarianCancer.
#LeadArticle Racial and sociodemographic disparities in the use of targeted therapies in advanced ovarian cancer patients with Medicare by @AnneKniselyMD. 🔎 @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official
0
1
11
RT @3gerardpique: Som únics. Mai podran ser com nosaltres. Amb tots els joves de la Masia. Quin recital. Quin orgull. ❤️.
0
24K
0
RT @IJGConline: 🚨 #Highlights from #ESGO2023 in Barcelona! 🇪🇸. New research findings & expert panel discussions are shaping the future of g….
0
11
0